Hello, everyone, and nice to see you again. As you can tell, we have survived yet another tech outage, but apologize for the spate of recent problems. We want you to know that we really are working on resolving the issues and appreciate your patience. Of course, we are turning to our usual coping mechanism - a cup or three of stimulation and, as always, invite you to join us. You deserve a pick-me-up, too, after all. Meanwhile, we have gathered the usual menu of tidbits and hope these help you along. So have a grand day and let us know if you hear anything interesting...
Glaxo Pays $227M For Basilea Eczema Drug (Pharma Times)
FDA Plans Warning Label For Drugs With Albumin (InPharma Technologist)
Lilly Boosts Stake In Chinese Generic Drugmaker (Wall Street Journal)
Wockhardt Sees Improving Margins Thanks To Generic Boom (Bloomberg News)
Lantus Does Not Raise Cancer Risk In Studies (Wall Street Journal)
Forest Labs Cuts Profit Outlook On Lexapro Competition (Associated Press)
UK's NICE Revises Amgen Bone Drug Guidance (Reuters)
Glaxo Rumored To Buy Biomarin (Daily Telegraph)
Sanofi Submits Lemtrada MS Drug To FDA And EMA (Pharma Times)
Avandia And Actos Are Linked To Vision Problems (HealthDay News)
Ampio Eye Drug For Diabetes Meets Study Goal, Stock Soars (Reuters)
EDITOR'S NOTE: Please check this post for updates during the day